Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $104,566 | $86,174 | $68,115 | $56,927 |
| - Cash | $1,140 | $904 | $1,361 | $1,045 |
| + Debt | $16,735 | $20,485 | $9,100 | $10,906 |
| Enterprise Value | $120,161 | $105,755 | $75,854 | $66,788 |
| Revenue | $26,027 | $22,123 | $18,790 | $15,529 |
| % Growth | 17.6% | 17.7% | 21% | – |
| Gross Profit | $20,242 | $17,128 | $14,014 | $12,045 |
| % Margin | 77.8% | 77.4% | 74.6% | 77.6% |
| EBITDA | $9,304 | $7,234 | $6,051 | $5,720 |
| % Margin | 35.7% | 32.7% | 32.2% | 36.8% |
| Net Income | $3,885 | $2,409 | $2,638 | $2,679 |
| % Margin | 14.9% | 10.9% | 14% | 17.3% |
| EPS Diluted | 11.24 | 7.39 | 8.44 | 8.62 |
| % Growth | 52.1% | -12.4% | -2.1% | – |
| Operating Cash Flow | $7,388 | $4,470 | $4,665 | $5,470 |
| Capital Expenditures | -$3,005 | -$4,943 | -$1,477 | -$370 |
| Free Cash Flow | $4,383 | -$473 | $3,188 | $5,100 |